Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » General » Sunitinib (Sutent) Receives PBS Listing for Metastatic pNET

Sunitinib (Sutent) Receives PBS Listing for Metastatic pNET

  • November 21, 2013
The Unicorn Foundation, as the peak organisation for neuroendocrine patients in Australia is committed to promoting and lobbying for equitable and timely access to medicines and treatments.

In recent months, the Unicorn Foundation's Dr John Leyden has been involved in lobbying the Pharmaceutical Benefits Advisory Committee (PBAC) and Federal Politicians of the need for sunitinib to be subsidised for the treatment of metastatic pancreatic neuroendocrine cancer. Sutent (sunitinib) has been shown to nearly double the progression free survival (PFS 11 months vs 5months) compared with placebo and in about 10% of patients their tumours shrank in size.

Our efforts were successful with sutent being placed on the Pharmaceutical Benefits Scheme (PBS) in late August. This is an extremely pleasing result which benefits our Australian patients by allowing our NET specialists the ability to better manage their disease and prolong life.

The Unicorn Foundation thanks the efforts of the PBAC and the Hon Peter Dutton for endorsing this listing which will potentially save our pNET patients millions of dollars a year.

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousUnicorn Foundation New Zealand
NextUpdat from Dr Christopher YatesNext

Related Posts

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

NECA Christmas and New Year Closure Details

Neuroendocrine Cancer Australia advises holiday closure dates from Tuesday 24 December 2024 to Friday 3 January 2025. We will reopen on Monday 6 January 2025.

Sydney Unicorn Get Together 2024

On the eve of Neuroendocrine Cancer Day, we were thrilled to join in this special patient-organised event, celebrating a record turnout of nearly 50 patients,

Team Janine completes City2Surf and raises over $9,000 for NECA

Team Janine walked arm in arm in memory of NET Patient Janine during City2Surf this weekend. Many thanks to Melinda, Sally, Margie, Julie, Kate, Georgia,

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin